Pharmaceuticals (Jun 2010)

Non-Steroidal Anti-Inflammatory Drugs in Alzheimer's Disease and Parkinson's Disease: Reconsidering the Role of Neuroinflammation

  • Amy H. Moore,
  • Matthew J. Bigbee,
  • Grace E. Boynton,
  • Colin M. Wakeham,
  • Hilary M. Rosenheim,
  • Christopher J. Staral,
  • James L. Morrissey,
  • Amanda K. Hund

DOI
https://doi.org/10.3390/ph3061812
Journal volume & issue
Vol. 3, no. 6
pp. 1812 – 1841

Abstract

Read online

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases with age as the greatest risk factor. As the general population experiences extended life span, preparation for the prevention and treatment of these and other age-associated neurological diseases are warranted. Since epidemiological studies suggested that non-steroidal anti-inflammatory drug (NSAID) use decreased risk for AD and PD, increasing attention has been devoted to understanding the costs and benefits of the innate neuroinflammatory response to functional recovery following pathology onset. This review will provide a general overview on the role of neuroinflammation in these neurodegenerative diseases and an update on NSAID treatment in recent experimental animal models, epidemiological analyses, and clinical trials.

Keywords